Thursday, April 9, 2026

MacroGenics gets FDA clearance to resume enrollment in Phase 2 LINNET trial

 

MacroGenics gets FDA clearance to resume enrollment in Phase 2 LINNET trial of lorigerlimab in gynecologic cancers

  • FDA lifted the partial clinical hold after MacroGenics implemented a revised trial protocol with additional patient safety measures.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.